BlackRock Fund Advisors recently announced the acquisition of new stake in Proteostasis Therapeutics Inc. (NASDAQ:PTI). The institutional investor has increased its shareholding in the Healthcare company by 2.60% to 1.08 million shares with purchase of 27226.0 shares. This fresh investment now brings its stake to 2.06% valued currently at $1.58 million. In addition, Winton Capital Management Ltd. raised its holdings by 0.14 million to 0.82 million shares. And Bridgeway Capital Management, Inc.. has lifted its position by 166.67% or 0.2 million shares – to 0.32 million shares.
With over 4.85 million Proteostasis Therapeutics Inc. (PTI) shares trading Tuesday and a closing price of $1.38 on the day, the dollar volume was approximately $6.7 million. The shares have shown a positive weekly performance of 1.47% and its price on 08/25/20 gained nearly 1.47%. Currently, there are 52.15M common shares owned by the public and among those 42.40M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for PTI have a consensus price objective of $5.00. The analysts have set the share’s price value over the next 12 months at a high of $8.00 and a low of $3.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Proteostasis Therapeutics Inc. stock is 2.00 for the next 12 months. But an upside of 82.75% will see the stock hit the forecast high price target while mean target price for the stock is $4.00.
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 1,283,919 shares.
The top 3 mutual fund holders in Proteostasis Therapeutics Inc. are Vanguard Total Stock Market Index, Delaware Healthcare Fund, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 1.2 million shares of the company’s stock, all valued at over $1.76 million. Vanguard Extended Market Index Fu now owns shares totaling to 0.97% of the shares outstanding.
Shares of Proteostasis Therapeutics Inc. (NASDAQ: PTI) opened at $1.29, down -$0.07 from a prior closing price of $1.36. However, the script later closed the day at $1.38, up 1.47%. The company’s stock has a 5-day price change of 1.47% and -6.12% over the past three months. PTI shares are trading -39.47% year to date (YTD), with the 12-month market performance up to 102.94% higher. It has a 12-month low price of $0.65 and touched a high of $4.72 over the same period. Currently, 4.85 million shares have been traded, compared to an average intraday trading volume of 1.13 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.92%, -2.53%, and -16.02% respectively.
Institutional ownership of Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares accounts for 17.60% of the company’s 52.15M shares outstanding. Mutual fund holders own 7.34%, while other institutional holders and individual stakeholders account for 9.31% and 34.84% respectively.
It has a market capitalization of $73.66M and a beta (3y monthly) value of 1.13. The earnings-per-share (ttm) stands at -$0.84. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.20% over the week and 8.94% over the month.
Analysts forecast that Proteostasis Therapeutics Inc. (PTI) will achieve an EPS of -$0.19 for the current quarter, -$0.19 for the next quarter and -$0.8 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.21 while analysts give the company a high EPS estimate of -$0.17. Comparatively, EPS for the current quarter was -$0.25 a year ago. Earnings per share for the fiscal year are expected to increase by 28.00%, and -9.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Proteostasis Therapeutics Inc. (PTI) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 1 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the PTI, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Outperform rating for the stock in a research note on October 18, 2018, with the firm’s price target at. Robert W. Baird coverage for the Proteostasis Therapeutics Inc. (PTI) stock in a research note released on December 12, 2017 offered a Outperform rating with a price target of $25. Guggenheim was of a view on April 18, 2016 that the stock is Neutral, while Robert W. Baird gave the stock Outperform rating on March 07, 2016, issuing a price target of $13. RBC Capital Mkts on their part issued Outperform rating on March 07, 2016.